Abstract Reduction of plasma LCAT activity has been observed in several conditions in which the size of HDL particles is increased; however, the mechanism of this reduction remains elusive. We investigated the plasma activity, mass, and in vivo catabolism of LCAT and its association with HDL particles in human apolipoprotein A-I transgenic, scavenger receptor class B type I knockout (hA-I Tg SR-BI 2/2 ) mice. Compared with hA-I Tg mice, hA-I Tg SR-BI 2/2 mice had a 4-fold higher total plasma cholesterol concentration, which occurred predominantly in 13-18 nm diameter HDL particles, a significant reduction in plasma esterified cholesterol-total cholesterol (EC/TC) ratio, and significantly lower plasma LCAT activity, suggesting a decrease in LCAT protein. However, LCAT protein in plasma, hepatic mRNA for LCAT, and in vivo turnover of 35 S-radiolabeled LCAT were similar in both genotypes of mice. HDL from hA-I Tg SR-BI 2/2 mice was enriched in sphingomyelin (SM), relative to phosphatidylcholine, and had less associated [ 35 S]LCAT radiolabel and endogenous LCAT activity compared with HDL from hA-I Tg mice. We conclude that the decreased EC/TC ratio in the plasma of hA-I Tg SR-BI 2/2 mice is attributed to a reduction in LCAT reactivity with SM-enriched HDL
S]LCAT radiolabel and endogenous LCAT activity compared with HDL from hA-I Tg mice. We conclude that the decreased EC/TC ratio in the plasma of hA-I Tg SR-BI 2/2 mice is attributed to a reduction in LCAT reactivity with SM-enriched HDL particles. - Epidemiological studies have shown a strong inverse relationship between plasma HDL concentrations and the incidence of coronary heart disease. The antiatherogenic effect of HDL is likely attributable to several beneficial effects of HDL, including inhibition of cytokine-induced expression of adhesion molecules by endothelial cells (1) , protection of LDLs from oxidation (2) , and its ability to stimulate reverse cholesterol transport (3), a process in which excess cholesterol is removed from extrahepatic tissues and transported to the liver for excretion in the bile. As excess free cholesterol (FC) in peripheral tissues is added to the surface of HDL particles, it is esterified with a fatty acid molecule from phospholipid by the plasma enzyme LCAT, resulting in a more hydrophobic cholesteryl ester (CE) molecule that partitions into the core of the HDL particle. This process also leads to an increase in HDL particle size. The LCAT reaction is essential for the maturation of nascent HDL particles in plasma, and a genetic deficiency of LCAT results in the near absence of normal HDL particles and the presence of plasma very low density and low density lipoprotein particles of abnormal size and shape.
Scavenger receptor class B type I (SR-BI) was identified as the HDL receptor that mediates selective HDL CE uptake by the liver and steroidogenic tissues (4) . Selective uptake of HDL CE was first suggested on the basis of CE uptake that exceeded that of HDL apolipoproteins (4-7). The physiological role of SR-BI in cholesterol metabolism and atherosclerosis development has been suggested by studies involving genetic ablation or overexpression of SR-BI in mice. SR-BI overexpression resulted in a decrease in plasma HDL cholesterol and an increase in biliary cholesterol concentration (8) (9) (10) . Overexpression of SR-BI in LDL receptor knockout mice fed a high-fat/ high-cholesterol diet strikingly reduced atherosclerotic lesions (11, 12) . In contrast, SR-BI knockout (SR-BI 2/2 ) mice showed an increase in plasma cholesterol concentration and a decrease in gallbladder cholesterol (13, 14) . In SR-BI and apolipoprotein E (apoE) double knockout mice, there were significant increases in plasma cholesterol concentration and extensive atherosclerosis compared with SR-BI or apoE single knockout mice, and the double knockout mice died of cardiovascular problems by 8 weeks of age (13, 15) . Similarly, LDL receptor knockout mice fed an atherogenic diet with reduced hepatic SR-BI expression showed an increase in atherosclerosis (16) . The mechanisms by which SR-BI exerts its atheroprotective effect remain unclear. Possible mechanisms include more favorable changes in plasma lipoprotein concentrations and composition, increased cholesterol flux out of the arterial wall, and increased selective CE uptake by the liver.
SR-BI 2/2 mice have enlarged plasma HDL particles that have an increase in the ratio of FC to total cholesterol (TC) and are enriched in apoE (14, 17) . The increased FC/TC ratio in these mice has been suggested to result from a decrease in LCAT-mediated cholesterol esterification (18, 19) . There are other experimental situations in which HDL enlargement is associated with decreased plasma LCAT activity. Fenofibrate treatment increased HDL particle size in both human apolipoprotein A-I transgenic (hA-I Tg ) and C57BL/6 mice by increasing phospholipid transfer protein (PLTP) gene expression through a peroxisome proliferator-activated receptor adependent pathway (20) , and plasma LCAT activity decreased as the dose of fenofibrate increased. The decrease in LCAT activity was mediated at the posttranscriptional level in hA-I Tg mice and at the transcriptional level in C57BL/6 mice. Human subjects with genetic cholesteryl ester transport protein (CETP) deficiency have an accumulation in plasma of enlarged HDL particles, enriched in apoE (21) , and lower plasma cholesterol esterification rates compared with normal subjects, with no difference in LCAT mass, suggesting that a functional LCAT deficiency exists in these subjects (22) . However, in a more recent study of homozygous CETP-deficient subjects, HDL 2 particles were observed to be enriched in LCAT and esterification rates of cholesterol in these particles were increased relative to HDL 2 particles from normal controls (23) .
A systematic study to determine the relationship between HDL particle enlargement and LCAT activity has not been performed, and the mechanisms responsible for the decrease in LCAT activity with HDL particle enlargement, observed in past studies, have not been explored. To address these issues, we created a new mouse strain that maximized HDL particle size heterogeneity by crossing SR-BI 2/2 mice with hA-I Tg . The enlargement in HDL particle size manifested by the elimination of SR-BI was exacerbated by the overexpression of human apoA-I, resulting in the accumulation of very large HDL particles (13-18 nm diameter) in plasma. Our results demonstrate that plasma LCAT activity was reduced by 70% in hA-I Tg SR-BI 2/2 mice compared with hA-I Tg mice as a result of a decreased association of LCAT with enlarged HDL particles and not as a result of a decreased plasma LCAT mass, decreased hepatic LCAT gene expression, or increased LCAT catabolism in vivo. (24) . Primer sequences used for genotyping were as follows: SR-BI wild-type allele (0.5 kb product), mSR-BI 13F (5 ¶-TGTTTGCTGCGCTCGGCGTTG-3 ¶) and mSR-BI 5R (5 ¶-TATCCTCGGCAGACCTGAGTCGTGT-3 ¶); SR-BI knockout allele (1.4 kb product), mSR-BI 3F (5 ¶-TGAAGGTGGTCTTCAAGAGCA-GTCCT-3 ¶) and mSR-BI 4R (5 ¶-GATTGGGAAGACAATAGCAGG-CATGC-3 ¶); and human apoA-I transgenic allele (1 kb product), AI-F Tg 3 ¶ (5 ¶-CAGCTCGTGCAGCTTCT-3 ¶) and AI-R Tg 5 ¶ (5 ¶-TGAACCCCCCCAGAGCC-3 ¶). The mice were housed in the Wake Forest University School of Medicine transgenic facility and maintained on a commercial diet (Prolab: RHM 3000). All protocols and procedures were approved by the Animal Care and Use Committee of the Wake Forest University School of Medicine.
METHODS

Animals
SR-BI
Plasma lipid, lipoprotein, and apolipoprotein analyses
Mice were bled at 8-12 weeks of age after a 4 h fast to measure plasma lipid concentrations and to perform lipoprotein analyses. Plasma TC, FC, triglyceride, and phospholipid concentrations were determined by enzymatic analysis (Wako Chemicals) (25) . Esterified cholesterol (EC) concentration was calculated as TC minus FC. HDL cholesterol was measured by enzymatic assay of the plasma supernatant after precipitation of apoB-containing lipoproteins with heparin-manganese (26) . Human plasma apoA-I concentration was quantified by ELISA using monospecific antiserum to monkey as described previously (27) .
Plasma lipoprotein distribution was determined by fast-protein liquid chromatography (FPLC). Pooled mouse plasma (150 ml) from each genotype was applied to two Superose 6 (1 3 30 cm) columns in series, and the TC concentration in each fraction (100 ml) was measured by enzymatic assay to obtain the lipoprotein cholesterol elution profile. Fractions were taken from the FPLC column for Western blot analysis using anti-human apoA-I and antimouse apoE primary polyclonal antibodies (Biodesign). The blots were developed using a horseradish peroxidase system (Pierce).
Analysis of plasma sphingomyelin and phosphatidylcholine content
Plasma from hA-I Tg and hA-I Tg SR-BI 2/2 mice was lipidextracted, and the phospholipid classes were separated by thinlayer chromatography and assayed for phosphorus content as described previously (28) , except that phosphatidylcholine (PC) and sphingomyelin (SM) bands from the thin-layer chromatography plate were analyzed directly for phosphorus (29) without prior lipid extraction from the silica gel. Blank lipid extracts were run as controls, and bands in the migration position of PC and SM were scraped and assayed for background color development. The blank extraction result was then subtracted from the corresponding PC or SM value.
nous LCAT assay were made by cholate dialysis using 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine, [ 3 H]cholesterol (50,000 dpm/mg), and apoA-I (80:5:1 molar ratio). Because of the 4-fold increase in plasma cholesterol in the hA-I Tg SR-BI 2/2 mice compared with hA-I Tg mice (see Results), the substrate concentration of rHDL cholesterol was increased from the routine value of 4 mM to 20 mM on the basis of pilot substrate saturation studies. The endogenous cholesterol esterification rate was measured by the method of Stokke and Norum (31) .
Hepatic LCAT mRNA and plasma LCAT mass measurement Hepatic LCAT mRNA abundance was measured by quantitative real-time PCR as described previously (26) . Liver samples from hA-I Tg and hA-I Tg SR-BI 2/2 mice were quick-frozen in liquid N 2 and stored at 280jC until use. Total RNA was isolated from liver samples using TRIzol reagent (Invitrogen), and 1 mg of total RNA was reverse-transcribed using the Omniscript reverse transcript reagents (Qiagen) according to the manufacturer's instructions to synthesize cDNA. Real-time PCR was performed using SYBR Green Master Mix (Applied Biosystems) in an ABI Prism 7700 Detection System to measure LCAT and GAPDH mRNA abundance. Primers used were as follows: LCAT-forward, 5 ¶-GCTGGCCTGGTAGAG-GAGATG-3 ¶; LCAT-reverse, 5 ¶-CCAAGGCTATGCCCAATGA-3 ¶; GAPDH-forward, 5 ¶-TGTGTCCGTCGTGGATCTGA-3 ¶; and GAPDH-reverse, 5 ¶-CCTGCTTCACCACCTTCTTGAT-3 ¶. Data were analyzed using the 2 2DDCt method (32). Plasma samples (0.2 ml) from hA-I Tg , hA-I Tg SR-BI 2/2 , and LCAT 2/2 mice (negative control) as well as purified mouse LCAT (33) were subjected to 4-16% SDS-PAGE followed by Western blot analysis using rabbit anti-mouse LCAT antiserum. LCAT was visualized using a horseradish peroxidase reagent (Pierce).
Isolation of 35 S-radiolabeled human recombinant LCAT
Human LCAT, radiolabeled with [ 35 S]methionine/cysteine, was produced and purified as described previously (34) . Activity of the purified LCAT enzymes was measured using an exogenous substrate (30), protein content was quantified using a chemical assay (35) , and 35 S radiolabel was determined by liquid scintillation spectroscopy. The specific activity of human LCAT was 4.6 3 10 5 cpm/mg LCAT protein. One microgram of [ 35 S]human recombinant lecithin:cholesterol acyltransferase (hrLCAT) protein was loaded on a 4-16% SDS-PAGE gel, and the LCAT protein was visualized by silver staining, Western blot analysis using rabbit anti-mouse LCAT antiserum, and phosphorimager analysis.
Association of endogenous mouse LCAT with plasma HDL
To determine the association of mouse LCAT mass and activity among plasma lipoproteins, 500 ml of plasma from hA-I Tg and hA-I Tg SR-BI 2/2 mice was injected onto FPLC Superose columns and 50 ml of each FPLC fraction was analyzed for LCAT activity using an exogenous rHDL substrate as described above.
Whole plasma from individual hA-I Tg and hA-I Tg SR-BI 2/2 mice was also fractionated on 4-30% nondenaturing gradient gels (36) . The proteins were transferred to nitrocellulose and developed with rabbit anti-mouse LCAT or preimmune antiserum. Plasma from LCAT 2/2 mice and purified hrLCAT was run on the gels as negative and positive controls, respectively. Pilot experiments demonstrated that human LCAT cross-reacts with the rabbit anti-mouse LCAT antiserum.
In vivo kinetic study
An in vivo kinetic study was performed with 35 S-radiolabeled human LCAT using conditions similar to those described previously (36) . Briefly, 2.5 3 10 5 cpm of the radiolabeled tracer was injected into the jugular vein of anesthetized recipient hA-I Tg and hA-I Tg SR-BI 2/2 mice. Blood samples were obtained by retroorbital bleeding at 10 and 30 min and at 1, 2, 3, 5, 8, and 24 h after dose injection. Radioactivity of plasma samples was counted using a liquid scintillation counter to determine plasma decay of the tracer.
Plasma (500 ml) from the 24 h time point of the plasma dieaway was fractionated by FPLC. Each fraction was assayed for cholesterol by enzymatic assay, for [ 35 S]LCAT radiolabel by liquid scintillation spectroscopy, and for LCAT activity using an exogenous rHDL substrate.
Statistical analysis
The results are expressed as means 6 SD. Differences among the genotypes of mice were analyzed using one-way ANOVA, followed by Tukey's multiple comparison test to identify individual differences. All statistical analyses were performed using InStat software (GraphPad Software, Inc., San Diego, CA).
RESULTS
Plasma lipid and lipoprotein analyses of hA-I
Tg SR-BI 2/2 mice Plasma lipid and human apoA-I concentrations for chow-fed hA-I Tg SR-BI 2/2 mice at 8-12 weeks of age are shown in Table 1 . Plasma TC, FC, and EC concentrations were 4.3-, 5.6-, and 3.9-fold higher in hA-I Tg SR-BI 2/2 mice compared with hA-I Tg mice. The EC/TC ratio was significantly lower in hA-I Tg SR-BI 2/2 mice compared with hA-I Tg mice, suggesting a possible defect in cholesterol esterification in the mice with inactive SR-BI. Plasma triglyceride and human apoA-I concentrations were similar among the three genotypes of mice.
To investigate the size distribution and apolipoprotein content of plasma lipoproteins, plasma samples from the mice were fractionated by FPLC, and apoA-I and apoE contents of the column fractions was determined by Western blot analysis. The FPLC profile of TC revealed marked enlargement of HDL particles in hA-I Tg SR-BI 2/2 mice, whereas hA-I Tg and hA-I Tg SR-BI 1/2 mice had similar FPLC profiles (Fig. 1) . Nondenaturing gradient gel electrophoresis analysis showed that the enlarged HDL particles in the plasma of hA-I Tg SR-BI 2/2 mice were 13-18 nm in diameter (data not shown). Separation of plasma by agarose gel electrophoresis, followed by staining with Sudan black (30) , demonstrated that all detectable lipoproteins in the plasma of the three genotypes of mice migrated in the a position, indicative of HDL (data not shown). The distribution of apoA-I for hA-I Tg mouse plasma was similar to that of cholesterol, and we found no evidence for another peak of HDL protein, indicative of small lipid-poor HDL particles, beyond fraction 66 (data not shown). However, the apoA-I distribution in hA-I Tg SR-BI 2/2 mouse plasma was skewed toward the larger HDL fractions (fractions [47] [48] [49] [50] [51] [52] [53] relative to that of hA-I Tg mouse plasma. The distribution of apoE was limited to the largest HDL particles (fractions [45] [46] [47] [48] [49] [50] and appeared to be increased in the plasma of hA-I Tg SR-BI 2/2 mice compared with hA-I Tg mice (data not shown), consistent with the findings of Rigotti et al. (14) , who also observed enlarged HDL particles enriched in apoE in SR-BI knockout mice.
Activities of plasma HDL remodeling enzymes
To determine whether hA-I Tg SR-BI 2/2 mice had reduced plasma LCAT activity, we measured the plasma activities of LCAT and two other plasma HDL remodeling proteins, HL and PLTP, using exogenous substrates. Plasma LCAT activity in hA-I Tg SR-BI 2/2 mice was 28% of that in hA-I Tg mice ( mice using exogenous rHDL substrate could be attributable to several mechanisms, including decreased LCAT production, increased plasma LCAT turnover, or inhibition of LCAT activity by the large HDL particles in plasma. To investigate LCAT production in our mice, we analyzed hepatic LCAT mRNA by quantitative real-time PCR, because LCAT is synthesized and secreted by the liver. There was no significant difference in hepatic LCAT mRNA expression between hA-I Tg SR-BI 2/2 and hA-I Tg mice ( Fig. 2A) . This result is also in agreement with another study that reported no differences in hepatic LCAT mRNA expression in wild-type and SR-BI 2/2 mice (19, 37). In addition, Western blot analysis of plasma samples from four representative mice of each genotype showed that plasma LCAT mass was similar in these mice (Fig. 2B) . These results indicate that reduced plasma LCAT activity in hA-I Tg SR-BI 2/2 mice was not attributable to changes in hepatic LCAT expression or plasma LCAT protein mass.
Plasma turnover of 35 S-labeled human LCAT
To determine whether plasma LCAT catabolism was affected in our mice, we measured the plasma decay of radiolabeled human LCAT in hA-I Tg and hA-I Tg SR-BI 2/2 recipient mice. Histidine-tagged human LCAT was radiolabeled metabolically with [ 35 S]methionine/cysteine and purified (34) . The [ 35 S]hrLCAT tracer migrated with authentic LCAT, as judged by silver staining, Western blot, and phosphorimager analysis of the tracer after SDS-PAGE (Fig. 3A) . The [ (Fig. 3B) . mice might be attributed to decreased interaction of plasma LCAT with HDL particles. We tested this hypothesis by determining the mass distribution of plasma LCAT among HDL particles for three individual mice of both genotypes by fractionating plasma HDL on 4-30% nondenaturing gradient gels and probing for LCAT distribution with rabbit anti-mouse LCAT antiserum (Fig. 4) . Plasma from hA-I Tg mice showed a rather diffuse distribution of LCAT in the 7.2-8.2 nm size range. However, plasma from hA-I Tg SR-BI 2/2 mice demonstrated a smaller, less diffuse band in the 7.2 nm size region of the gel that is smaller than most plasma HDL particles (30) . Two controls demonstrated the specificity of the LCAT banding pattern between 7.2 and 8.2 nm: 1) the lack of a LCAT band in that region in plasma from LCAT 2/2 mice; and 2) no detectable band in that region when blots were developed with preimmune serum. These results suggested that plasma LCAT in hA-I Tg SR-BI 2/2 mice was not likely associated with HDL particles or with lipidpoor HDL.
In vivo association of [ 35 S]LCAT with HDL particles
The in vivo association of [ 35 S]LCAT with plasma HDL was determined at the end of the turnover study for recipient mice by FPLC fractionation of the 24 h time point plasma, followed by quantification of radiolabel and cholesterol in each fraction. We also measured LCAT activity in each fraction using an exogenous rHDL substrate. Significantly more of the recovered [
35 S]LCAT tracer was associated with normal-sized HDL particles (Fig. 5A , fractions 54-64; 7.5-12 nm diameter) in the terminal plasma samples of hA-I Tg mice compared with plasma from hA-I Tg SR-BI 2/2 mice (35.8 6 2.0% vs. 26.0 6 2.1%; mean 6 SEM; n 5 3, P 5 0.027). This trend was also observed for the elution of mouse LCAT activity in the plasma samples; the mouse LCAT activity peak (Fig. 5B) and LCAT protein (data not shown) were shifted to the left in plasma of Tg and hA-I Tg SR-BI 2/2 mice. Total RNA was isolated from liver samples, and 1 mg was reversetranscribed into cDNA. Quantitative real-time PCR was performed using SYBR Green. The data were normalized using GAPDH as an internal control and expressed as fold change relative to a hA-I mice, a LCAT 2/2 mouse, and purified mouse LCAT were fractionated on SDS-PAGE, and LCAT was detected by Western blot analysis using rabbit antiserum against mouse LCAT. ) mice. Plasma samples were obtained from 8-12 week old chow-fed mice of the indicated genotype after a 4 h fast. Plasma (150 ml) was fractionated on Superose 6 fast-protein liquid chromatography (FPLC) columns, and the total cholesterol (TC) concentration of each fraction was measured by enzymatic assay. An aliquot of fractions 45-66 was separated by SDS-PAGE, and the proteins were transferred to nitrocellulose. The nitrocellulose blots were then probed with anti-human apolipoprotein A-I (h ApoA-I) or anti-mouse apoE (m ApoE) antibodies and developed with horseradish peroxidase.
hA-I
Tg mice compared with that of hA-I Tg SR-BI 2/2 mice and overlapped more with the elution position of small HDL, suggesting that more LCAT was associated with HDL particles in hA-I Tg mice. The difference in the elution of human LCAT (Fig. 5A, fractions 56-62 ) and endogenous mouse LCAT activity (Fig. 5B, fractions 61-67 ) in the HDL region may represent a difference in HDL particle substrate preference for human and mouse LCAT or the fact that only a small percentage of the injected human LCAT remains in plasma after the 24 h turnover, and the remaining fraction of LCAT may not reflect the initial distribution of LCAT in plasma at earlier time points.
Enrichment of plasma with SM in hA-I Tg SR-BI 2/2 mice An increase in plasma lipoprotein SM content has been shown to decrease plasma LCAT activity by decreasing the binding of LCAT to lipoprotein particle surfaces (38, 39) . To determine whether an increase in plasma SM content might be responsible for less LCAT bound to HDL particles in hA-I Tg SR-BI 2/2 mouse plasma, we measured the SM/PC ratio in plasma (Table 1 ). There was a 3-fold increase (P , 0.007) in the SM/PC ratio in the plasma of hA-I Tg SR-BI 2/2 mice compared with hA-I Tg mice.
Association of rHDL [ 3 H]cholesterol with plasma HDL after LCAT assay
The results obtained to this point suggested that LCAT protein in hA-I Tg SR-BI 2/2 mouse plasma is not decreased relative to that in hA-I Tg mouse plasma, but its distribution is skewed toward the lipoprotein-free or lipid-poor HDL fraction of plasma. LCAT in the lipoprotein-free or lipidpoor HDL fraction of plasma should be reactive with rHDL; however, LCAT activity in hA-I Tg SR-BI 2/2 mouse plasma measured using rHDL was 28% of that in hA-I Tg mouse plasma (Table 1) . To address this apparent paradox, we hypothesized that [ 3 H]cholesterol in rHDL substrate particles exchanged into large HDL particles in hA-I Tg SR-BI 2/2 mouse plasma during the LCAT assay, resulting in a decrease in measured LCAT activity attributable to the relatively poor reactivity of large HDL particles. To test this hypothesis, LCAT assays were performed using plasma from C57BL/6, hA-I Tg , and hA-I Tg SR-BI 2/2 mice or water (blank) as the LCAT source and rHDL as the exogenous substrate. After the assay, the incubation mixture was fractionated by FPLC and [
3 H]cholesterol distribution in the eluted fractions was determined. Results for CE formation are shown in Fig. 6A . As anticipated, the CE formation rate for hA-I Tg SR-BI 2/2 plasma was 25% of that in hA-I Tg mouse plasma and the value for C57BL/6 plasma was intermediate. Fractionation of the incubation mixtures by FPLC showed that the elution Tg and hA-I Tg SR-BI 2/2 mice were fractionated on 4-30% nondenaturing gradient gels. The proteins were then transferred to nitrocellulose paper, and LCAT was detected by Western blot analysis using rabbit anti-mouse LCAT antiserum (left panel) or preimmune antiserum (right panel). Plasma from a LCAT 2/2 mouse and rhLCAT, which cross-reacts with anti-mouse LCAT antiserum, was run as negative and positive controls, respectively. Hydrated diameter (nm) of standard proteins is shown at left of the blots.
1/1 and 2/2 denote the SR-BI genotypes of the mice. Functional LCAT deficiency in transgenic miceprofile of rHDL radiolabel was similar for samples that used C57BL/6 and hA-I Tg mouse plasma as the LCAT source and paralleled that of the elution profile for rHDL incubated without plasma (i.e., water control) (Fig. 6B) . However, the profile of rHDL radiolabel in the hA-I Tg SR-BI 2/2 plasma incubation was shifted to the left into a region of the column where large HDL particles elute. Fractions from the FPLC column were pooled and lipidextracted, and FC and EC radiolabel were quantified. The pool corresponding to the large HDL elution region (fractions 46-56) contained 57% of the total [
3 H]FC in the hA-I Tg SR-BI 2/2 plasma incubation but only 29, 17, and 16% in hA-I Tg plasma, C57BL/6 plasma, and water blank incubations, respectively. These data support the hypothesis that LCAT activity measured with rHDL substrate in hA-I Tg SR-BI 2/2 plasma is reduced compared with that in hA-I Tg plasma because the [ 3 H]cholesterol in the rHDL particles exchanges into the large HDL particles.
DISCUSSION
We have described a functional LCAT deficiency in a novel animal model (hA-I Tg SR-BI
2/2
) that has extremely high plasma cholesterol concentrations (800 mg/dl). The relative LCAT deficiency manifests as a significant decrease in the EC/TC ratio in plasma and in LCAT activity, measured by an exogenous substrate assay. A similar observation has been made in other publications, in which the appearance of large HDL particles in plasma is described as accompanied by a decrease in the EC/TC ratio in plasma or a decrease in LCAT activity, suggesting that this could be a general response to the accumulation of large HDL in plasma (17, 20, 40, 41) . However, the mechanism of the decreased LCAT activity in plasma has not been investigated. Our studies demonstrate that, despite a 70% decrease in plasma LCAT activity, plasma LCAT mass, hepatic mRNA for LCAT, and plasma catabolism of LCAT are similar between hA-I Tg and hA-I Tg SR-BI 2/2 mice. To explain this apparent paradox, we propose two possibilities. First, we provide evidence that LCAT is redistributed to the nonlipoprotein or lipid-poor HDL fraction of plasma in hA-I Tg SR-BI 2/2 mice and, therefore, is un- , and C57BL/6 mice or water (control) as the source of LCAT protein, as described in Methods. Bars represent means of duplicate incubations, and error bars denote the range of the duplicates. CE, cholesteryl ester. B: Duplicate incubations of the LCAT assay described in A were fractionated by FPLC, and [ available for cholesterol esterification on HDL particles. This could account for the decreased EC/TC ratio in the plasma of hA-I Tg SR-BI 2/2 mice relative to hA-I Tg mice. We hypothesized that the redistribution of LCAT in plasma was attributable to an accumulation of SM in HDL particles as a result of the lack of functional SR-BI. Previous studies have shown that SM enrichment of lipoproteins inhibits LCAT activity by preventing its binding to HDL (39) , and analysis of the plasma SM content of hA-I Tg SR-BI 2/2 mice showed that the SM/PC ratio was increased by 3-fold relative to plasma of hA-I Tg mice. Second, the decrease in plasma LCAT activity measured by exogenous rHDL substrate appears to result from a redistribution of radiolabeled cholesterol from highly reactive rHDL particles to large (13-18 nm in diameter) HDL particles that are relatively unreactive with LCAT, resulting in an apparent decrease in LCAT activity in hA-I Tg SR-BI 2/2 mouse plasma. This study provides new insight into the mechanism of functional LCAT deficiency that occurs in hA-I Tg SR-BI 2/2 mice and may be applicable to other metabolic situations in which HDL particle size is increased.
Enlarged HDL particles, sometimes referred to as HDL 1 , have also been observed in the plasma of several genetically altered mouse models (14, 17, (42) (43) (44) , humans with CETP deficiency (22) , and mice treated with fenofibrate (20), a ligand for the transcription factor peroxisome proliferatoractivated receptor a. Fenofibrate appears to increase HDL particle size by inhibiting hepatic SR-BI expression (45, 46) . In most of these studies, apoE enrichment of these enlarged HDL particles has been documented. Several of these studies have directly measured LCAT activity in plasma using exogenous rHDL substrate particles, whereas other studies have documented a decrease in the CE/TC ratio in plasma, suggesting a decrease in plasma LCAT. It was speculated that the decrease in plasma LCAT activity in one study resulted from decreased LCAT binding to HDL and increased catabolism of the enzyme (20) . However, this hypothesis has never been tested directly, and no study has reported on the in vivo catabolism of LCAT.
We also obtained evidence for LCAT deficiency in a new mouse model that was generated by crossing SR-BI knockout mice with hA-I Tg mice to generate hA-I Tg SR-BI 2/2 mice. These mice had, in plasma, very high HDL concentrations, the appearance of apoE-enriched HDL 1 (Fig. 1) , a significant decrease in EC/TC ratio, and a decrease in LCAT activity compared with hA-I Tg mice (Table 1) . We hypothesized that the LCAT deficiency was attributable to increased plasma LCAT catabolism, as had been proposed in a previous publication (20) . We found that plasma LCAT protein (Fig. 2B) , hepatic mRNA for LCAT ( Fig. 2A) , and plasma decay of [ 35 S]rhLCAT (Fig. 3) were similar in both genotypes of mice, suggesting that our hypothesis was incorrect.
Previous studies have reported that 80-90% of LCAT in human plasma is bound to HDL particles (47) . To explain our experimental results, we hypothesized that LCAT protein was redistributed to the nonlipoprotein fraction of plasma in hA-I Tg SR-BI 2/2 mice and was not available for the esterification of HDL FC. To test our hypothesis, we used two approaches. First, nondenaturing gradient gel electrophoresis showed a distinctly faster migration pattern for LCAT in a region of the gel that is smaller than a-migrating HDL particles, suggesting that less LCAT protein was associated with HDL in hA-I Tg SR-BI 2/2 mouse plasma (Fig. 4) . Second, FPLC analysis of plasma demonstrated that relatively less [ 35 S]rhLCAT was associated with the HDL cholesterol peak in hA-I Tg SR-BI 2/2 mouse plasma compared with that in hA-I Tg mouse plasma (Fig. 5A ). In addition, mouse LCAT activity in hA-I Tg SR-BI 2/2 mouse plasma, measured by an exogenous rHDL substrate, eluted in a later position compared with that of hA-I Tg mouse plasma and after the HDL cholesterol peak (Fig. 5B) . Although these results can explain the decrease in plasma EC/TC ratio, they cannot explain why LCAT did not bind to normal-sized HDL particles, which are not decreased in hA-I Tg SR-BI 2/2 mouse plasma (Fig. 5, fractions 55-66 (38, 39) . In our study, we observed a 3-fold increase in the SM/PC ratio in hA-I Tg SR-BI 2/2 mouse plasma compared with hA-I Tg plasma, supporting the hypothesis that enrichment of HDL particles in plasma results in a redistribution of LCAT to the nonlipoprotein fraction of plasma. SR-BI has been reported to transfer SM from lipoproteins into cells, and this may represent an important pathway for the clearance of plasma SM (48, 49) . The absence of functional SR-BI could result in the enrichment of HDL SM, which could be exchanged among HDL particles in plasma by PLTP (50) , resulting in the net enrichment of SM in all plasma lipoprotein particles. This, in turn, could lead to decreased binding of LCAT to lipoproteins and less cholesterol esterification in plasma. An alternative explanation for our data may be that the absence of SR-BI leads to a unique perturbation of HDL particle structure that results in inhibition of LCAT binding and activity unrelated to the increase in SM.
In previous studies, LCAT activity in human plasma was highly correlated with LCAT mass (51) . This has led to the practice of equating LCAT activity, determined with exogenous rHDL substrate particles, with the relative amount of LCAT protein in plasma. However, this assumption has not been adequately tested in plasma samples with high concentrations of HDL or enlarged HDL particles. Our results suggest that radiolabeled cholesterol in highly reactive rHDL particles exchanges into larger, less reactive HDL particles during the incubation, resulting in the measurement of less LCAT activity (Fig. 6 ). This result was verified using an endogenous LCAT assay in which radiolabeled cholesterol is incorporated into endogenous lipoproteins in plasma (31, 52) . In five independent experiments, the percentage endogenous esterification rate for plasma from hA-I Tg SR-BI 2/2 mice was 13.8 6 1.9%
(mean 6 SEM) of that in plasma from hA-I Tg mice. In two of those experiments in which plasma FC was measured, the absolute endogenous cholesterol esterification rate in hA-I Tg SR-BI 2/2 mouse plasma was 60% of that observed in hA-I Tg mouse plasma (Table 1) . These results suggest that in spite of a 5.5-fold increase in plasma FC concentration in hA-I Tg SR-BI 2/2 mouse plasma (Table 1) , there was a deficiency in LCAT-mediated CE formation relative to hA-I Tg mouse plasma. Whether the decrease in LCAT-mediated cholesterol esterification is a phenotype of other genetically altered mouse models that have high HDL concentrations or an increase in the concentration of large HDL particles is unknown. However, our results suggest caution in interpreting lower than normal LCAT activity in the plasma of mice with increased HDL concentrations without supportive data regarding LCAT protein mass.
Enlarged HDL particles have been referred to as "dysfunctional" because of their association with increased atherosclerosis as well as ovarian dysfunction (18, 53) . The exact nature of the particle that causes the dysfunction is poorly defined, but a recent study suggests that it may not be the size of the HDL particle per se but the increase in FC that is critical to the dysfunction (18) . The increase in HDL FC may prevent cellular cholesterol efflux to HDL, because the FC chemical gradient that drives FC flux from cells to HDL is lost. Evidence from several studies suggests that the increase in HDL FC is not the result of LCAT deficiency in plasma. In one study, LCAT mass was normal in SR-BI 2/2 mouse plasma (19) . In another study, a 10-fold overexpression of LCAT in SR-BI 2/2 mice had a minor effect on the FC/TC ratio and did not correct the ovarian dysfunction (18) . Finally, overexpression of LCAT actually resulted in dysfunctional HDL (53) . The results from all of these studies suggest that LCAT protein is present in plasma but unable to bind to HDL particles. Our results as well as previous studies indicate that this may be attributable to an increased SM content of HDL preventing LCAT binding to HDL surfaces (38, 39) . In support of this idea is a recent study in which HDL 2 particles from CETP-deficient subjects were observed to have increased ABCG1-mediated cholesterol efflux from macrophages that was dependent on LCAT activity (23) . The HDL 2 particles from CETP-deficient subjects had 10-fold more LCAT and a 50% reduction in SM/PC ratio compared with their normal counterparts. Thus, dysfunctional HDL particles may result in metabolic conditions in which the SM content of HDL is increased, resulting in decreased LCAT-mediated cholesterol esterification and increased HDL FC.
